Cost-utility analysis of a treatment advice to discontinue inappropriate long-term antidepressant use in primary care
The DOI matches its Crossref record; 16 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Antidepressant prescriptions have increased exponentially, burdening health care costs. OBJECTIVE: To evaluate the costs and effects of an antidepressant cessation advice in case of inappropriate long-term use in primary care, i.e. long-term usage without a (current) indication. METHODS: A economic evaluation during 1-year follow-up was performed, from a societal perspective, as part of a cluster-randomised controlled clinical trial (PANDA). Costs were assessed using the Trimbos/iMTA questionnaire for costs associated with psychiatric illness. Health-related quality of life was measured using the EuroQol 5D. Outcome was costs per quality adjusted life year (QALY). Missing values were estimated using multiple imputation, bootstrap simulations were performed to address the uncertainty surrounding the incremental cost-effectiveness ratios (ICERs). RESULTS: There was no difference in average QALYs between the intervention (0.70) and control group (0.72) [difference -0.02 (95% CI -0.05 to 0.10)]. The intervention group, however, was less expensive than the control group (total costs €3636 versus €5267, respectively). Most cost-effectiveness pairs were located in the south-west quadrant of the cost-effectiveness plane, implying the intervention was less effective but also less costly. The ICER of the pooled data was €70,180, meaning that for one QALY lost, €70,180 is saved. CONCLUSIONS: This study shows that an antidepressant cessation advice given to patients (and their FPs) with inappropriate long-term antidepressant usage, albeit not effective, does seem to result in a reduction of societal costs. This reduction in costs is mostly due to reduction of productivity losses, possibly due to patient empowerment and loss of stigma.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Prompting alone is therefore insufficient in supporting patients to discontinue antidepressants, which indicates there are other factors preventing GPs from attempting to withdraw patients from antidepressants.”
From Helping people discontinue long-term antidepressants: views of health professionals in UK primary care (2019) · cites this paper as [18]
In the citing paper
“Prompting GPs to review patients eligible for withdrawal was tested in a trial in the Netherlands and found to be ineffective, with 6% of patients discontinuing antidepressants in the intervention group and 8% in the control group.18”
From Helping people discontinue long-term antidepressants: views of health professionals in UK primary care (2019) · cites this paper as [18]
Citations
Cites
EuroQol: the current state of play
Brooks, R. (1996) · Health Policy · doi:10.1016/0168-8510(96)00822-6 · Cited by 5,815
Multiple imputation in health‐are databases: An overview and some applications
Rubin, D. B., & Schenker, N. (1991) · Statistics in Medicine · doi:10.1002/sim.4780100410 · Cited by 1,550 · cited 1×
“Instead of filling in a single value for each missing value, Rubin’s multiple imputation procedure generates ‘m’ data sets, each of which replaces each missing value with a plausible value, that represent the uncertainty about the right value to impute (15).”
Walters, S. J., & Brazier, J. E. (2005) · Quality of Life Research · doi:10.1007/s11136-004-7713-0 · Cited by 1,341
Rouse, D. (1990) · Journal of Clinical Pathology · doi:10.1136/jcp.43.9.787-d · Cited by 1,179
The friction cost method for measuring indirect costs of disease
Koopmanschap, M. A., Rutten, F. F. H., van Ineveld, B. M., & van Roijen, L. (1995) · Journal of Health Economics · doi:10.1016/0167-6296(94)00044-5 · Cited by 1,137 · cited 1×
“Thus productivity cost was only counted for as long as it costs to replace someone, after this period the costs fall back to zero (11).”
[Measuring the quality of life in economic evaluations: the Dutch EQ-5D tariff].
Lamers, L. M., Stalmeier, P. F. M., McDonnell, J., Krabbe, P. F. M., & Busschbach, J. J. V. (2005) · PubMed · Cited by 697
Stange, K. C., & Ferrer, R. L. (2009) · The Annals of Family Medicine · doi:10.1370/afm.1023 · Cited by 235 · cited 1×
“This result also illustrates the paradox of primary care (18).”
Cost-effectiveness in clinical trials: using multiple imputation to deal with incomplete cost data
Burton, A., Billingham, L. J., & Bryan, S. (2007) · Clinical Trials · doi:10.1177/1740774507076914 · Cited by 137 · cited 2×
“This results in statistically valid inferences that properly reflect the uncertainty due to missing values (16).”
Brouwer, W. B. F., & Koopmanschap, M. A. (2005) · PharmacoEconomics · doi:10.2165/00019053-200523020-00002 · Cited by 100
Much Cheaper, Almost as Good: Decrementally Cost-Effective Medical Innovation
Nelson, A. L., Cohen, J. T., Greenberg, D., & Kent, D. M. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-9-200911030-00011 · Cited by 92 · cited 1×
“The selling price of a QALY (willingness to accept to lose a QALY) seems to be larger than the buying price of a QALY (willingness to pay to gain a QALY) (20).”
Overuse of Antidepressant Drugs for the Treatment of Depression
Jureidini, J. N., & Tonkin, A. (2006) · CNS Drugs · doi:10.2165/00023210-200620080-00002 · Cited by 90 · cited 1×
“Studies suggest that a large proportion of antidepressant treatment is inappropriate (5), consequently the question rises whether the use of antidepressant drugs can be reduced in order to lower the burden on medical costs.”
NHG-Standaard Depressie (tweede herziening)
van Weel-Baumgarten, E. M., van Gelderen, G., Grundmeijer, H. G. L. M., Licht-Strunk, E., van Marwijk, H., van Rijswijk, E., Tjaden, B., Verduijn, M. M., Wiersma, T., Burgers, J. S., et al. (2012) · Huisarts en Wetenschap · Cited by 67
Association of antipsychotic polypharmacy with health service cost: a register-based cost analysis
Baandrup, L., Sørensen, J. R., Lublin, H., Nordentoft, M., & Glenthoj, B. Y. (2011) · The European Journal of Health Economics · doi:10.1007/s10198-011-0308-0 · Cited by 56 · cited 1×
“Moreover, polypharmacy with psychotropic drugs leads to high mental health care and community costs (increase of ~20%) (6).”
Supina, A. L., Johnson, J. A., Patten, S. B., Williams, J. V. A., & Maxwell, C. J. (2007) · Quality of Life Research · doi:10.1007/s11136-006-9159-z · Cited by 49 · cited 1×
“The EQ-5D has been proven suitable for calculating QALYs in economic evaluation of health care interventions for patients with mental disorders (13).”
Polypharmacy in general practice.
Schæfer, K., Maerkedahl, H., Birk, H. O., & Henriksen, L. O. (2010) · PubMed · Cited by 15
Muskens, E., Eveleigh, R., Lucassen, P., van Weel, C., Spijker, J., Verhaak, P., Speckens, A., & Voshaar, R. O. (2013) · BMC Family Practice · doi:10.1186/1471-2296-14-6 · Cited by 13 · cited 1×
“The study design of the PANDA study of the cluster randomised controlled trial has been published elsewhere (8).”
Self-citation
Research works printed but not linked: 2
- 2012, HUISARTS EN WETENSCHAP, 55, 252
- Lamers, 2005, Nederlands tijdschrift voor geneeskunde, 149, 1574
Cited by
Davies, J., & Read, J. (2019) · Addictive Behaviors · doi:10.1016/j.addbeh.2018.08.027 · Cited by 387
Reeve, E., Thompson, W., & Farrell, B. (2017) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2016.12.021 · Cited by 331
Combining multiple imputation and bootstrap in the analysis of cost‐effectiveness trial data
Brand, J., van Buuren, S., le Cessie, S., & van den Hout, W. (2019) · Statistics in Medicine · doi:10.1002/sim.7956 · Cited by 131
Van Leeuwen, E., van Driel, M. L., Horowitz, M. A., Kendrick, T., Donald, M., De Sutter, A. I., Robertson, L., & Christiaens, T. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013495.pub2 · Cited by 90
Strategies to reduce use of antidepressants
Kendrick, T. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14475 · Cited by 96
“discontinuing antidepressants in the intervention group compared to 8% in the control group.(31,32) Prompting the prescriber to review treatment seems, therefore,”
Metadata
- Authors
- Eveleigh, R., Grutters, J., Muskens, E., Oude Voshaar, R., van Weel, C., Speckens, A., & Lucassen, P.
- Affiliations
- Radboud University Medical Center (NL)
- Radboud University Nijmegen (NL)
- Corresponding author
- Eveleigh, R.
- Venue
- Family Practice
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-08-13
- Volume
- 31
- Issue
- 5
- Pages
- 578-584
- ISSN
- 0263-2136 (ISSN-L)
- 1460-2229
- OpenAlex
- W2141292129
- Cited by
- 28
- References
- 17
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 3 · 2023: 1 · 2022: 1 · 2021: 2 · 2020: 5 · 2019: 4 · 2018: 3 · 2017: 2
- FWCI
- 1.66
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Family Practice (publishedVersion)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
- ANU Open Research (Australian National University) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Funders
- Radboud Universiteit
- Radboud Universitair Medisch Centrum
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Health Sciences › Health Professions › General Health Professions › Healthcare cost, quality, practices
- Keywords
- antidepressant discontinuation, cost-effectiveness, quality-adjusted life years, primary care, prescribing patterns, social costs, productivity loss, stigma, patient empowerment
- MeSH terms
- Adult, Aged, Antidepressive Agents, Anxiety Disorders, Cost-Benefit Analysis, Depressive Disorder, Female, Humans, Male, Middle Aged, Primary Health Care, Quality of Life, Program Evaluation, Correspondence as Topic, Health Care Costs, Cost of Illness, Practice Guidelines as Topic, Quality-Adjusted Life Years, Inappropriate Prescribing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.